WO2016038521A8 - Pharmaceutical compositions of liraglutide - Google Patents
Pharmaceutical compositions of liraglutide Download PDFInfo
- Publication number
- WO2016038521A8 WO2016038521A8 PCT/IB2015/056775 IB2015056775W WO2016038521A8 WO 2016038521 A8 WO2016038521 A8 WO 2016038521A8 IB 2015056775 W IB2015056775 W IB 2015056775W WO 2016038521 A8 WO2016038521 A8 WO 2016038521A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical compositions
- liraglutide
- relates
- present
- compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title abstract 2
- 108010019598 Liraglutide Proteins 0.000 title abstract 2
- 229960002701 liraglutide Drugs 0.000 title abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 abstract 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 abstract 1
- 235000019797 dipotassium phosphate Nutrition 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 235000019800 disodium phosphate Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising: (i) liraglutide; (ii) a buffer selected from the group consisting of dipotassium phosphate, sodium bicarbonate, and disodium phosphate anhydrous; (iii) propylene glycol; and (iv) a preservative. The compositions of the present invention remain stable after exposure to multiple freeze-thaw cycles or after being subjected to elevated temperature. It also relates to processes for the preparation of said pharmaceutical compositions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2558DE2014 | 2014-09-08 | ||
| IN2558/DEL/2014 | 2014-09-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016038521A1 WO2016038521A1 (en) | 2016-03-17 |
| WO2016038521A8 true WO2016038521A8 (en) | 2016-06-16 |
Family
ID=55458399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2015/056775 WO2016038521A1 (en) | 2014-09-08 | 2015-09-04 | Pharmaceutical compositions of liraglutide |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016038521A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535835A (en) * | 2016-11-22 | 2019-12-12 | バイオコン リサーチ リミテッドＢｉｏｃｏｎ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | Pharmaceutical composition of GLP-1 analogue |
| CA3082033A1 (en) | 2017-08-24 | 2019-02-28 | Novo Nordisk A\S | Glp-1 compositions and uses thereof |
| PE20211492A1 (en) * | 2018-10-26 | 2021-08-11 | Novo Nordisk As | STABLE COMPOSITIONS OF SEMAGLUTIDE AND USES OF THE SAME |
| EP3897570A1 (en) | 2018-12-19 | 2021-10-27 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising glp-1 analogue |
| WO2020208541A1 (en) | 2019-04-08 | 2020-10-15 | Enzene Biosciences Limited | Composition comprising glp-1 analogue |
| WO2021123228A1 (en) | 2019-12-18 | 2021-06-24 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
| MX2022009844A (en) | 2020-02-18 | 2022-09-05 | Novo Nordisk As | Glp-1 compositions and uses thereof. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5562510B2 (en) * | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー／エス | Stable formulation of modified GLP-1 |
| PL3300721T3 (en) * | 2003-11-20 | 2019-08-30 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| CA2708762A1 (en) * | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
-
2015
- 2015-09-04 WO PCT/IB2015/056775 patent/WO2016038521A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016038521A1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016038521A8 (en) | Pharmaceutical compositions of liraglutide | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| HRP20220075T1 (en) | A liquid formulation comprising nicotine for aerosol administration | |
| PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| MX2017008518A (en) | Isoquinoline compounds for the treatment of hiv. | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| HK1255162A1 (en) | Apelin receptor agonists and methods of use | |
| MX2022001292A (en) | Stereochemically enriched compositions for delivery of nucleic acids. | |
| TN2017000452A1 (en) | Compositions of obeticholic acid and methods of use | |
| MX2018001990A (en) | Compositions comprising a pi3k inhibitor and an hdac inhibitor. | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| MX378732B (en) | Solid forms | |
| MX2016016666A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
| MX2016015093A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
| NZ721952A (en) | Delayed release compositions of linaclotide | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| HK1248069A1 (en) | Desacetoxytubulysin h and analogs thereof | |
| IL283430B (en) | Formulations that include recombinant acid alpha-glucosidase | |
| MY191590A (en) | 9h-pyrrolo-dipyridine derivatives | |
| BR112017000246A2 (en) | compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound or salt | |
| WO2017008136A3 (en) | Flourinated cbd compounds, compositions and uses thereof | |
| MX387731B (en) | ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE. | |
| MX2019004580A (en) | Pharmaceutical formulations and methods of making the same. | |
| MY182634A (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| EA201691792A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON VILDAGLIPTINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15840750 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15840750 Country of ref document: EP Kind code of ref document: A1 |